Skip to main content
recep.adiyaman
Vision About Experience Education Skills Publications Tools Newsletter Updates Podcasts Blog Contact CV Subscribe
All Issues
Older Newer
Daily Signal May 08, 2026 · 10 min read

Issue #104: Identification of paucinervin D as a natural sphingosine-1-phosphate receptor 1 agonist: Insights from pharmacophore modeling, docking, molecular dynamics simulations, and density functional theory.

Protein Design Digest #104: Identification of paucinervin D as a natural sphingosine-1-phosphate rec…

Share X LinkedIn
Protein Design Daily

Building something in Protein Design?

I love collaborating on new challenges. Let's build together.

LinkedIn Email

Subscribe to Protein Design Digest

Daily curated signals from arXiv, PubMed, and BioRxiv.

Signal of the Day

Identification of paucinervin D as a natural sphingosine-1-phosphate receptor 1 agonist: Insights from pharmacophore modeling, docking, molecular dynamics simulations, and density functional theory.

Sphingosine-1-phosphate receptor 1 (S1PR1), a member of the G protein-coupled receptor (GPCR) family, is a crucial therapeutic target for various diseases. Activation of S1PR1 has been recognized as an effective therapeutic strategy for multiple sclerosis (MS), inflammatory bowel disease (IBD), and psoriasis. Natural products (NPs) serve as a rich source of bioactive compounds for drug discovery. Here, we aimed to discover novel S1PR1 agonists from NPs via multi-level virtual screening (VS). Using a validated HipHop pharmacophore model, we screened a database containing 54,642 NPs, followed by molecular docking. Based on binding mode analysis, four candidate S1PR1 agonists (NPC323626, NPC264112, NPC469907, and NPC22192) were selected. Subsequent molecular dynamics (MD) simulations and binding free energy calculations confirmed the stability of the receptor-ligand complexes and their binding affinities. Among the four candidates, NPC469907 exhibited the strongest binding affinity for S1PR1, with a value of -58.08 ± 0.13 kJ/mol. Furthermore, hydrogen bonds formed between NPC469907 and Glu121 of S1PR1 were found to be essential for receptor activation. Quantum mechanical calculations further revealed that the phenyl-ring-attached hydrogen site in NPC469907 could be modified without compromising its ability to activate S1PR1. The analysis of Absorption, Distribution, Metabolism, Excretion, and Toxicity (ADMET) indicated that NPC469907 possessed favorable pharmacokinetic properties and low toxicity. In conclusion, our study identified NPC469907 as a promising natural S1PR1 agonist and established an effective VS strategy for the discovery of novel S1PR1 agonists.

Why this matters: Enhances small-molecule or peptide docking accuracy for targeted drug discovery.

Also Worth Reading

A Systematic Survey and Benchmark of Deep Learning for Molecular Property Prediction in the Foundation Model Era.

Molecular property prediction integrates quantum chemistry, cheminformatics, and deep learning to connect molecular structure with physicochemical and biological behavior. This survey traces four complementary paradigms, including Quantum, Descriptor Machine Learning, Geometric Deep Learning, and Foundation Models, and outlines a unified taxonomy linking molecular representations, model architectures, and interdisciplinary applications. Benchmark analyses integrate evidence from both widely used data sets and data sets reflecting industry perspectives, encompassing quantum, physicochemical, physiological, and biophysical domains. The survey examines current standards in data curation, splitting strategies, and evaluation protocols, highlighting challenges including inconsistent stereochemistry, heterogeneous assay sources, and reproducibility limitations under random or poorly defined splits. These observations motivate the modernization of benchmark design toward more transparent, time- and scaffold-aware methodologies. We further propose three forward-looking directions: (i) physics-aware learning embedding quantum consistency, (ii) uncertainty-calibrated foundation models for trustworthy inference, and (iii) realistic multimodal benchmark ecosystems integrating computational and experimental data. Repository: https://github.com/Zongru-Li/Survey-and-Benchmarks-of-DL-for-Molecular-Property-Prediction-in-the-Foundation-Model-Era.

Molecular docking approaches in mycetoma: Toward improved patient management.

Mycetoma is a neglected tropical disease characterised by chronic, granulomatous inflammation of the subcutaneous tissues, often leading to disfigurement, disability, and significant socioeconomic burdens. Caused by a diverse array of bacterial and fungal pathogens, eumycetoma is predominantly driven by Madurella mycetomatis, and current treatment strategies are limited and often ineffective. Conventional antifungal therapies, such as itraconazole, require prolonged administration, frequently combined with surgical interventions, yet cure rates remain suboptimal, and recurrence is common. The formidable protective grain, comprising microbial material, melanin, and host-derived substances, acts as a physical and biochemical barrier, impeding the penetration and efficacy of drugs. Additionally, issues such as toxicity, resistance, and high costs further complicate management, underscoring the urgent need for novel therapeutic strategies. Recent advancements in computational drug discovery, particularly molecular docking, offer promising avenues to accelerate the identification of effective anti-mycetoma agents. Molecular docking simulates the interaction between small molecules and target proteins, enabling rapid virtual screening of large compound libraries, including natural products, existing drugs, and synthetic molecules, against key pathogenic targets. This structure-based approach helps prioritise candidates with high binding affinity, guiding subsequent experimental validation and reducing both time and financial costs associated with traditional drug development. When integrated with artificial intelligence (AI) and machine learning (ML), these methods can enhance predictive accuracy, uncover novel bioactive scaffolds, and facilitate the repurposing of FDA-approved drugs such as montelukast and vilanterol. Key molecular targets in M. mycetomatis include enzymes and pathways critical for pathogen survival and virulence, notably cytochrome P450 (CYP51), dihydrofolate reductase (DHFR), chitin synthase, melanin biosynthesis pathways, and metal ion acquisition systems. Melanin production, via DHN-melanin, DOPA-melanin, and pyomelanin pathways, contributes to grain pigmentation and structural integrity, while metal ions such as iron and zinc are vital for enzymatic activities, grain formation, and fungal virulence. Disrupting metal ion homeostasis through targeting zincophores, siderophores, and zinc-binding proteins represents a promising therapeutic strategy to weaken grain robustness and enhance drug penetration. Despite the potential of molecular docking, limitations such as reliance on homology models, static protein structures, and the absence of cellular context necessitate complementary approaches, including molecular dynamics simulations and in vitro validation. These combined efforts can refine candidate compounds, optimise binding affinities, and predict pharmacokinetic properties. Furthermore, integrating docking results with clinical data and global collaboration platforms can accelerate the discovery of affordable, effective treatments tailored to endemic regions. In conclusion, leveraging molecular docking and computational methods to target essential M. mycetomatis pathways offers a promising frontier in mycetoma research. By identifying novel inhibitors and understanding pathogen biology at a molecular level, these approaches can inform targeted therapies, reduce treatment durations, and improve patient outcomes. Future research should focus on validating computational predictions experimentally and translating these findings into clinical practice, with an emphasis on accessible, cost-effective interventions for vulnerable populations affected by this neglected disease.

Gene Expression, Docking and Machine Learning in Malaria Drug Discovery: A Systematic Review.

Background Malaria remains a significant and worldwide health threat with increasing resistance to current treatments, stimulating the demand for innovative approaches in pursuing drug discovery. This systematic review integrates the progress made from 2014 through 2024 regarding molecular methods like gene expression profiling, molecular docking and machine learning to understand the biology of Plasmodium and identify new drug targets and compounds, focusing on herbal remedies and computational methods. Methodology Several studies were found using a PRISMA-guided search of PubMed, Scopus and Web of Science (64 studies found). The data extracted were gene expression outcomes, docking affinities, ML models and experimental validations (in vitro/in vivo). Results Molecular docking emerged as the dominant technique (32.37%), followed by in vitro antiplasmodial assays (14.39%), ADMET profiling (10.79%) and gene expression studies (3.60%). RNA-seq analysis revealed key host and parasite genes modulated by herbal treatments, including those involved in apoptosis and inflammation. Notably, compounds like isorhamnetin and myricetin 3-O-glucoside showed exceptionally high binding affinities to Plasmepsin II and Plasmodium falciparum lactate dehydrogenase (PfLDH) (ΔG Conclusion Multiomics, docking and ML integration improve the target identification and prioritise the compounds. This review illustrates the great potential of molecular techniques for the development of drugs against antimalarial helicases that are not resistant to drug therapy. However, in vivo data holes and methodology inconsistency limit clinical translation. Future work should include standardisation of protocols and studies of synergistic combinations of phytochemicals.

Research & AI Updates

From the Industry

Quick Reads

Fabrication and Biological Evaluation of 3D Bioprinted GelMA Scaffolds with Bone Marrow-Derived Mesenchymal Stem Cells for Osteochondral Tissue Engineering.

Repairing osteochondral defects remains a significant therapeutic challenge due to the complex hierarchical structure of the tissue, while existing treatment strategies are largely palliative rather than curative. Read more →

Bioinformatics-Driven Target Discovery in Skin Photoaging and Preliminary Validation of the Natural Compound Acteoside

Abstract Objective To identify differentially expressed genes (DEGs), key pathways, and potential active compounds associated with skin photoaging using bioinformatics approaches, and to validate the interventional effects and molecular mechanisms of candidate compounds through cellular experiments, thereby highlighting the central role of bioinformatics in target and drug discovery. Read more →

The pivotal role of NF-κB in polymyxin B toxicity: insights from integrated network toxicology and experimental assays.

Polymyxin B remains a first-line therapeutic option against Gram-negative bacterial infections; however, its clinical utility is substantially limited by dose-limiting toxicity, the mechanisms of which remain incompletely elucidated. Read more →

3D confinement reshapes RNA folding and enhances circularisation in the Zika virus

Many RNA molecules function within confined environments, but the effect of confinement on RNA folding remains poorly understood. Read more →

Genetic confirmation of terbinafine resistance in Trichophyton rubrum mediated by the squalene epoxidase Leu393Phe mutation via targeted gene replacement.

Terbinafine (TBF) is a first-line allylamine antifungal used to treat dermatophytosis caused by Trichophyton species, targeting squalene epoxidase (SQLE). Read more →

Three-color single-molecule fluorescence resonance energy transfer to study macromolecular dynamics.

Single-molecule fluorescence resonance energy transfer (smFRET) is a powerful tool to probe macromolecular dynamics. Read more →

Dauricine Mitigates Hypoxia through Targeting ESR1, PIK3CA, and MTOR: A Network Pharmacology and Molecular Dynamics Simulation Investigation

Hypoxia is a prevalent pathophysiological condition. Read more →

Identification of naringenin chalcone as a key gut metabolite for bladder cancer intervention: An integrated strategy combining network pharmacology and molecular dynamics simulation.

Bladder cancer (BCa) is a prevalent malignancy with high recurrence. Read more →

Pipeline Tip

Use GPU-accelerated MD refinement to lift model quality in under 2 hours.

Resources & Tools

The protein structure is the language of life; design is its poetry. — Recep Adiyaman

BS HF DK